TY - JOUR T1 - Diagnosis and management of psoriatic arthropathy in primary care JF - British Journal of General Practice JO - Br J Gen Pract SP - 424 LP - 425 DO - 10.3399/bjgp14X681181 VL - 64 IS - 625 AU - Morag Lenman AU - Sonya Abraham Y1 - 2014/08/01 UR - http://bjgp.org/content/64/625/424.abstract N2 - Psoriasis arthritis (PsA) is a chronic, inflammatory disease, affecting predominantly skin and joints (Figure 1). Skin psoriasis develops before arthritis in the majority of cases, with a typical time lag of 5 to 10 years. However, around 20% of PsA patients never develop psoriasis.1 The prevalence of psoriasis in the UK is approximately 2% of the adult population.2Figure 1. Typical clinical presentation of psoriasis arthritis. The white arrow denotes dactylitis and the black arrows denote psoriasis.Epidemiological studies indicate that between 10% and 30% of people with psoriasis will go on to develop PsA, giving a population prevalence for PsA of 0.4%. Out of 40 million adults in England, around 160 000 would be expected to have PsA. According to the National Institute for Health and Care Excellence (NICE), only 6200 people in England are currently registered to receive biological therapies for PsA, representing 4% of this population. Of the 350 000 people in the UK who have rheumatoid arthritis (RA), 35 000 (10%) are on biological therapies.PsA appears to be underdiagnosed not only in the UK but also abroad. According to the American Psoriasis Foundation, there are over 7 million adults in the US who have psoriasis but only 520 000 (7.4%) of these patients have … ER -